Insider · CIK 0001349193
Wesley Clark
Files at IBRX (ImmunityBio, Inc.). First filing -, latest -.
In brief
Wesley Clark files SEC Form 4 as director at IBRX (ImmunityBio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Wesley Clark has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +65,600 | $0.00 | $0 | 65,600 | Jun 10, 2026 |
| Jun 18, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +162,786 | $0.00 | $0 | 162,786 | Jun 20, 2025 |
Questions about Wesley Clark
Answered from the filings on this page, as of the latest one.
Is Wesley Clark buying or selling?
Wesley Clark has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Wesley Clark's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Wesley Clark has 0.
Where does Wesley Clark file Form 4?
Wesley Clark has filed Form 4 at IBRX (ImmunityBio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.